FDA expands approved use of drug to treat liver cancer

On April 27, the U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. It’s the first FDA-approved treatment for a liver cancer in almost a decade. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here